MITOFATIGUE
What it found
No result yet.
What it measured
Main measures
Quantification of fatigue and comparision with sNfL, sGFAP, and mitochondrial activity
The patients will be tested yearly. All markers will be evaluated prospectively. The Time Frame is from date of randomization up to 5 years
Disability progressionRelapsesMRI lesionsBlood or spinal fluid markersFatigue
Other measures (1)
Correlation of genetic characteristics, biomarkers, fatigue tests, and mitochondrial status with the disease burden.
5 years after the last reqruited patient
Disability progressionMRI lesionsBlood or spinal fluid markersFatigue
Who could take part
MS (type not specified) · 18 and over
Inclusion Criteria: Clinical diagnosis of multiple sclerosis using McDonald2017 criteria Patients indicated to immunomodulatory treatment Exclusion Criteria: Multimorbidities
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The study is focused on several independent quantifiable biomarkers (sNfL, sGFAP, mitochondrial activity, genetics and fatigue tests) to obtain more detailed information about MS and its progression. Based on the results, investigator will further attempt to predict the course of the disease and manage the therapy more effectively to prevent worsening of the patient's condition.
Loading reviews and guidelines…
History
Started
Jan 2024
Main results due
Dec 2027
Finished
Dec 2028
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error